CME/CE

Hear an expert discussion between Dr. Komal Jhaveri and Dr. Virginia Kaklamani as they examine the evolving role of oral selective estrogen receptor degraders (SERDs), including PROTACs and novel combination strategies, in the treatment of ER+/HER2− metastatic breast cancer. Drs. Jhaveri and Kaklamani review emerging efficacy and safety data, considerations for treatment selection after prior endocrine therapy and CDK4/6 inhibitor exposure, the role of ESR1 mutation testing in sequencing therapy, and emerging combination and frontline treatment data. The discussion also highlights practical, interdisciplinary approaches to monitoring and managing adverse events to support evidence-based clinical decision-making in practice.

Update: On September 4, 2026, the FDA granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK 4/6 inhibitor therapy, based on an FDA-authorized test.

Update: On September 18, 2026, the FDA approved imlunestrant in combination with abemaciclib, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an …

In this Patient-Clinician Connection, Dr. Gianluigi Savarese uses a clinical case to demonstrate shared decision-making strategies for managing chronic and recurrent hyperkalemia in patients with chronic kidney disease and heart failure receiving guideline-directed medical therapy (GDMT). The discussion examines how to address patient concerns about hyperkalemia while supporting the continued use of evidence-based therapies that improve cardiovascular outcomes. Practical considerations for potassium management, including the role of oral potassium binders and individualized treatment planning, are also reviewed.

Despite the well-known efficacy of anti-VEGF agents, a significant proportion of patients with DME or nAMD continue to show persistent or recurrent retinal fluid on OCT. This activity brings together expert faculty to discuss how to identify patients with VEGF-refractory disease and optimize management. Attendees will also gain insight into emerging therapeutic pathways, including Wnt, the angiopoietin (Ang)/Tie2 pathway, and tyrosine kinase inhibitors (TKIs), that may improve retinal vascular stability and treatment durability.

Using a real-world patient case, Dr. Stephen Greene and Dr. Carolyn Lam explore strategies to optimize care for patients with heart failure with reduced ejection fraction (HFrEF) who remain at elevated risk despite guideline-directed medical therapy (GDMT). The discussion examines the importance of avoiding clinical inertia, addressing persistent residual risk, and using biomarkers such as NT-proBNP to guide treatment decisions. Faculty also review the mechanism of action of the soluble guanylate cyclase stimulator vericiguat and evidence from the VICTORIA and VICTOR trials evaluating its use across a spectrum of ambulatory HFrEF populations, as well as findings from the VELOCITY study supporting a 5-mg starting dose and simplified titration to the target dose. Practical guidance is provided on integrating vericiguat with established HFrEF therapies, including patient selection, dosing, and tolerability, with the goal of reducing the risk of cardiovascular death and worsening heart failure in appropriate patients.

This online educational activity reviews the clinical evidence supporting anti-CD38 monoclonal antibody–based combinations as foundational frontline therapy for patients with newly diagnosed multiple myeloma. Faculty examine pivotal clinical trial data and current NCCN Guidelines across transplant-eligible and transplant-ineligible populations, highlighting the impact of anti-CD38 therapy on depth and durability of response. The program utilizes patient cases to emphasize fitness- and risk-adapted approaches to treatment selection that take patient comorbidities, frailty, cytogenetic risk, and treatment goals into account. Through real-world clinical perspectives, participants will learn strategies to implement guideline-concordant regimens, optimize treatment delivery, and improve outcomes in community practice.

This online educational activity reviews the clinical evidence supporting anti-CD38 monoclonal antibody–based combinations as foundational frontline therapy for patients with newly diagnosed multiple myeloma. Faculty examine pivotal clinical trial data and current NCCN Guidelines across transplant-eligible and transplant-ineligible populations, highlighting the impact of anti-CD38 therapy on depth and durability of response. The program utilizes patient cases to emphasize fitness- and risk-adapted approaches to treatment selection that take patient comorbidities, frailty, cytogenetic risk, and treatment goals into account. Through real-world clinical perspectives, participants will learn strategies to implement guideline-concordant regimens, optimize treatment delivery, and improve outcomes in community practice.

This online educational activity reviews the clinical evidence supporting anti-CD38 monoclonal antibody–based combinations as foundational frontline therapy for patients with newly diagnosed multiple myeloma. Faculty examine pivotal clinical trial data and current NCCN Guidelines across transplant-eligible and transplant-ineligible populations, highlighting the impact of anti-CD38 therapy on depth and durability of response. The program utilizes patient cases to emphasize fitness- and risk-adapted approaches to treatment selection that take patient comorbidities, frailty, cytogenetic risk, and treatment goals into account. Through real-world clinical perspectives, participants will learn strategies to implement guideline-concordant regimens, optimize treatment delivery, and improve outcomes in community practice.

This online educational activity reviews the clinical evidence supporting anti-CD38 monoclonal antibody–based combinations as foundational frontline therapy for patients with newly diagnosed multiple myeloma. Faculty examine pivotal clinical trial data and current NCCN Guidelines across transplant-eligible and transplant-ineligible populations, highlighting the impact of anti-CD38 therapy on depth and durability of response. The program utilizes patient cases to emphasize fitness- and risk-adapted approaches to treatment selection that take patient comorbidities, frailty, cytogenetic risk, and treatment goals into account. Through real-world clinical perspectives, participants will learn strategies to implement guideline-concordant regimens, optimize treatment delivery, and improve outcomes in community practice.

Most cases of hypoparathyroidism have an obvious cause, but what about the patients who don't fit the usual pattern? Explore autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic condition that is frequently overlooked yet carries important implications for diagnosis, management, and family screening. Learn when to suspect ADH1, how to navigate the diagnostic work-up, and why genetic testing plays a critical role in confirming the diagnosis. Discover how identifying the underlying cause can influence a patient's clinical course and long-term care strategy. You'll walk away with the tools needed to discuss genetic testing with patients and explain its relevance to family members.

Mineralocorticoid receptor antagonists (MRAs) have been shown to prevent many of the deleterious effects of aldosterone. Despite a strong level of evidence and prominent place in guidelines for HFrEF, the steroidal MRAs (sMRAs) spironolactone and eplerenone remain underutilized for reasons including hyperkalemia, side effects, and poor tolerability. The data for sMRAs in patients with HFmrEF and HFpEF are inconclusive and controversial. Nonsteroidal MRA (nsMRA) therapy has distinct features from sMRAs; the nsMRA finerenone has demonstrated effectiveness in reducing the risk of adverse cardiovascular outcomes in HFmrEF and HFpEF. In this activity, HF expert faculty members will explain the evidence with sMRAs in HFrEF, describe the distinct profiles of sMRAs and nsMRAs, and interpret clinical evidence with sMRAs and nsMRAs in HFmrEF and HFpEF.